Literature DB >> 20660187

Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.

Xavier Dervillez1, Volker Klaukien, Ralf Dürr, Joachim Koch, Alexandra Kreutz, Thomas Haarmann, Michaela Stoll, Donghan Lee, Teresa Carlomagno, Barbara Schnierle, Kalle Möbius, Christoph Königs, Christian Griesinger, Ursula Dietrich.   

Abstract

During HIV-1 entry, binding of the viral envelope glycoprotein gp120 to the cellular CD4 receptor triggers conformational changes resulting in exposure of new epitopes, the highly conserved CD4-induced (CD4i) epitopes that are essential for subsequent binding to chemokine receptor CCR5 or CXCR4. Due to their functional conservation, CD4i epitopes represent attractive viral targets for HIV-1 entry inhibition. The aim of the present study was to select peptide ligands for CD4i epitopes on native dualtropic (R5X4) HIV-1 envelope (Env) glycoproteins by phage display. Using CD4-activated retroviral particles carrying Env from the R5X4 HIV-1 89.6 strain as the target, we performed screenings of random peptide phage libraries under stringent selection conditions. Selected peptides showed partial identity with amino acids in the extracellular domains of CCR5/CXCR4, including motifs rich in tyrosines and aspartates at the N terminus known to be important for gp120 binding. A synthetic peptide derivative (XD3) corresponding to the most frequently selected phages was optimized for Env binding on peptide arrays. Interestingly, the optimized peptide could bind specifically to gp120 derived from HIV-1 strains with different coreceptor usage, competed with binding of CD4i-specific monoclonal antibody (MAb) 17b, and interfered with entry of both a CCR5 (R5)-tropic and a CXCR4 (X4)-tropic Env pseudotyped virus. This peptide ligand therefore points at unique properties of CD4i epitopes shared by gp120 with different coreceptor usage and could thus serve to provide new insight into the conserved structural details essential for coreceptor binding for further drug development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660187      PMCID: PMC2937783          DOI: 10.1128/JVI.00165-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

Authors:  C D Rizzuto; R Wyatt; N Hernández-Ramos; Y Sun; P D Kwong; W A Hendrickson; J Sodroski
Journal:  Science       Date:  1998-06-19       Impact factor: 47.728

3.  Direct measurement of angles between bond vectors in high-resolution NMR.

Authors:  B Reif; M Hennig; C Griesinger
Journal:  Science       Date:  1997-05-23       Impact factor: 47.728

4.  Antigen selection from an HIV-1 immune antibody library displayed on yeast yields many novel antibodies compared to selection from the same library displayed on phage.

Authors:  D R Bowley; A F Labrijn; M B Zwick; D R Burton
Journal:  Protein Eng Des Sel       Date:  2007-01-22       Impact factor: 1.650

5.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

6.  Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1.

Authors:  Aran F Labrijn; Pascal Poignard; Aarti Raja; Michael B Zwick; Karla Delgado; Michael Franti; James Binley; Veronique Vivona; Christoph Grundner; Chih-Chin Huang; Miro Venturi; Christos J Petropoulos; Terri Wrin; Dimiter S Dimitrov; James Robinson; Peter D Kwong; Richard T Wyatt; Joseph Sodroski; Dennis R Burton
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.

Authors:  Weizao Chen; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-28       Impact factor: 11.205

8.  Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning.

Authors:  Mei Yun Zhang; Yuuei Shu; Donna Rudolph; Ponraj Prabakaran; Aran F Labrijn; Michael B Zwick; Renu B Lal; Dimiter S Dimitrov
Journal:  J Mol Biol       Date:  2004-01-02       Impact factor: 5.469

9.  Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers.

Authors:  Makobetsa Khati; Michael Schüman; Jamal Ibrahim; Quentin Sattentau; Siamon Gordon; William James
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Derivation of dihedral angles from CH-CH dipolar-dipolar cross-correlated relaxation rates: a C-C torsion involving a quaternary carbon atom in epothilone A bound to tubulin.

Authors:  Teresa Carlomagno; Víctor M Sánchez; Marcel J J Blommers; Christian Griesinger
Journal:  Angew Chem Int Ed Engl       Date:  2003-06-06       Impact factor: 15.336

View more
  3 in total

1.  A Novel High-Throughput Screening Assay to Identify Inhibitors of HIV-1 gp120 Protein Interaction with DC-SIGN.

Authors:  Thuong H Tran; Rasha El Baz; Andrea Cuconati; James Arthos; Pooja Jain; Zafar K Khan
Journal:  J Antivir Antiretrovir       Date:  2011-10-17

Review 2.  Phages and HIV-1: from display to interplay.

Authors:  Sylvie Delhalle; Jean-Claude Schmit; Andy Chevigné
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

3.  A neutralization assay for chikungunya virus infections in a multiplex format.

Authors:  Christopher Weber; Renate König; Matthias Niedrig; Petra Emmerich; Barbara S Schnierle
Journal:  J Virol Methods       Date:  2014-02-16       Impact factor: 2.014

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.